Hormonal
GLP-1 receptor agonists (GLP-1RAs) improve hepatic steatosis, liver dysfunction enzymes, and glycemic control in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
If you have fatty liver disease (MASLD/MASH), especially with diabetes or obesity, GLP-1 medications (like Semaglutide or Liraglutide) are a proven treatment option. They not only help lower blood sugar and promote weight loss but also directly improve liver health by reducing fat and inflammation. While lifestyle changes are foundational, these medications offer a powerful tool when lifestyle changes alone are insufficient or hard to maintain long-term. Consult your doctor to see if a GLP-1 RA is appropriate for your specific liver condition.
GLP-1RAs have been explored in MASH patients with evident improvement in liver dysfunction enzymes, glycemic control, and weight loss.
Why this rating
The paper reviews multiple Phase 2 RCTs and animal studies, providing strong clinical and mechanistic evidence, though long-term outcomes and triple agonists are still emerging.
Source
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
Lampros Chrysavgis et al. · International Journal of Molecular Sciences · 2024
DOI 10.3390/ijms25073832
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →